Clinical Trial Update: Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of Tarceva (erlotinib) in combination with rapamycin for children with low-grade gliomas, with or without neurofibromatosis type 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma
• Neurofibromatosis Type

Drugs mentioned

• Rapamycin (sirolimus)
• Tarceva (erlotinib)

Snippet

Sponsor: Roger Packer | Conditions: Low-grade Gliomas | Phase 1 | Status: COMPLETED